Long-term activation of the innate immune system in atherosclerosis

Seminars in Immunology

Volumn 28, Issue 4, 2016, Pages 384-393

  Christ, Anette ^a,b   Bekkering, Siroon ^d   Latz, Eicke ^a,b,c   Riksen, Niels P ^d  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Changed dietary components; Epigenetic reprogramming; Hyperlipidemia; Immuno metabolism; Innate immune memory; Trained innate immunity

Indexed keywords

2 OXOGLUTARIC ACID; 3 HYDROXYBUTYRIC ACID; ACETYL COENZYME A; ADENOSINE TRIPHOSPHATE; CARNITINE; FLAVINE ADENINE NUCLEOTIDE; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; S ADENOSYLMETHIONINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRICHOSTATIN A; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ANKYLOSING SPONDYLITIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CHLAMYDIAL PNEUMONIA; DIET; DNA METHYLATION; EPIGENETICS; FOOD COMPOSITION; GENE SILENCING; GENETIC TRANSCRIPTION; GOUT; HISTONE ACETYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; IMMUNOLOGICAL MEMORY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PORPHYROMONAS GINGIVALIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; GENETIC EPIGENESIS; HETEROLOGOUS IMMUNITY; IMMUNE SYSTEM; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ANIMALS; ATHEROSCLEROSIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; EPIGENESIS, GENETIC; HUMANS; IMMUNE SYSTEM; IMMUNITY, HETEROLOGOUS; IMMUNITY, INNATE; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION;

EID: 84963969033     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2016.04.004     Document Type: Review

References (111)

1. [1] Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., et al. Heart disease and stroke statistics-2016 update: a report from the American heart association. Circulation 133 (2016), e38–e360.
2. [2] Thompson, R.C., Allam, A.H., Lombardi, G.P., Wann, L.S., Sutherland, M.L., Sutherland, J.D., et al. Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations. Lancet 381 (2013), 1211–1222.
3. [3] Hansson, G.K., Hermansson, A., The immune system in atherosclerosis. Nat. Immunol. 12 (2011), 204–212.
4. [4] Virchow, R., Cellular pathology. As based upon physiological and pathological histology. Lecture XVI-Atheromatous affection of arteries. 1858. Nutr. Rev. 47 (1989), 23–25.
5. [5] Rosenfeld, M.E., Campbell, L.A., Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb. Haemost. 106 (2011), 858–867.
6. [6] Corrales-Medina, V.F., Musher, D.M., Shachkina, S., Chirinos, J.A., Acute pneumonia and the cardiovascular system. Lancet 381 (2013), 496–505.
7. [7] Dutta, P., Courties, G., Wei, Y., Leuschner, F., Gorbatov, R., Robbins, C.S., et al. Myocardial infarction accelerates atherosclerosis. Nature 487 (2012), 325–329.
8. [8] Nahrendorf, M., Swirski, F.K., Innate immune cells in ischaemic heart disease: does myocardial infarction beget myocardial infarction?. Eur. Heart J. 37 (2016), 868–872.
9. [9] De Rosa, V., Galgani, M., Santopaolo, M., Colamatteo, A., Laccetti, R., Matarese, G., Nutritional control of immunity: balancing the metabolic requirements with an appropriate immune function. Semin. Immunol. 27 (2015), 300–309.
10. [10] Netea, M.G., Quintin, J., van der Meer, J.W., Trained immunity: a memory for innate host defense. Cell Host Microbe 9 (2011), 355–361.
11. [11] Ensan, S., Li, A., Besla, R., Degousee, N., Cosme, J., Roufaiel, M., et al. Self-renewing resident arterial macrophages arise from embryonic CX3CR1(+) precursors and circulating monocytes immediately after birth. Nat. Immunol. 17 (2016), 159–168.
12. [12] Hansson, G.K., Libby, P., The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6 (2006), 508–519.
13. [13] Robbins, C.S., Hilgendorf, I., Weber, G.F., Theurl, I., Iwamoto, Y., Figueiredo, J.L., et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat. Med. 19 (2013), 1166–1172.
14. [14] Boring, L., Gosling, J., Cleary, M., Charo, I.F., Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998), 894–897.
15. [15] Potteaux, S., Gautier, E.L., Hutchison, S.B., van Rooijen, N., Rader, D.J., Thomas, M.J., et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe−/− mice during disease regression. J. Clin. Invest. 121 (2011), 2025–2036.
16. [16] Moore, K.J., Sheedy, F.J., Fisher, E.A., Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol. 13 (2013), 709–721.
17. [17] Duewell, P., Kono, H., Rayner, K.J., Sirois, C.M., Vladimer, G., Bauernfeind, F.G., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464 (2010), 1357–1361.
18. [18] Shah, P.K., Mechanisms of plaque vulnerability and rupture. J. Am. Coll. Cardiol. 41 (2003), 15S–22S.
19. [19] Colin, S., Chinetti-Gbaguidi, G., Staels, B., Macrophage phenotypes in atherosclerosis. Immunol. Rev. 262 (2014), 153–166.
20. [20] Swirski, F.K., Libby, P., Aikawa, E., Alcaide, P., Luscinskas, F.W., Weissleder, R., et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest. 117 (2007), 195–205.
21. [21] Tacke, F., Alvarez, D., Kaplan, T.J., Jakubzick, C., Spanbroek, R., Llodra, J., et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest. 117 (2007), 185–194.
22. [22] Kaynar, A.M., Yende, S., Zhu, L., Frederick, D.R., Chambers, R., Burton, C.L., et al. Effects of intra-abdominal sepsis on atherosclerosis in mice. Crit. Care, 18, 2014, 469.
23. [23] Tabas, I., Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10 (2010), 36–46.
24. [24] Tall, A.R., Yvan-Charvet, L., Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol. 15 (2015), 104–116.
25. [25] Murphy, A.J., Akhtari, M., Tolani, S., Pagler, T., Bijl, N., Kuo, C.L., et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J. Clin. Invest. 121 (2011), 4138–4149.
26. [26] Westerterp, M., Gourion-Arsiquaud, S., Murphy, A.J., Shih, A., Cremers, S., Levine, R.L., et al. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell 11 (2012), 195–206.
27. [27] Yvan-Charvet, L., Pagler, T., Gautier, E.L., Avagyan, S., Siry, R.L., Han, S., et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 328 (2010), 1689–1693.
28. [28] Seijkens, T., Hoeksema, M.A., Beckers, L., Smeets, E., Meiler, S., Levels, J., et al. Hypercholesterolemia-induced priming of hematopoietic stem and progenitor cells aggravates atherosclerosis. FASEB J. 28 (2014), 2202–2213.
29. [29] van Kampen, E., Jaminon, A., van Berkel, T.J., Van Eck, M., Diet-induced (epigenetic) changes in bone marrow augment atherosclerosis. J. Leukoc. Biol. 96 (2014), 833–841.
30. [30] Wierda, R.J., Geutskens, S.B., Jukema, J.W., Quax, P.H., van den Elsen, P.J., Epigenetics in atherosclerosis and inflammation. J. Cell. Mol. Med. 14 (2010), 1225–1240.
31. [31] Wierda, R.J., Rietveld, I.M., van Eggermond, M.C., Belien, J.A., van Zwet, E.W., Lindeman, J.H., et al. Global histone H3 lysine 27 triple methylation levels are reduced in vessels with advanced atherosclerotic plaques. Life Sci. 129 (2015), 3–9.
32. [32] Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten, L.A., Ifrim, D.C., Saeed, S., et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 17537–17542.
33. [33] Quintin, J., Saeed, S., Martens, J.H., Giamarellos-Bourboulis, E.J., Ifrim, D.C., Logie, C., et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 12 (2012), 223–232.
34. [34] Leentjens, J., Kox, M., Stokman, R., Gerretsen, J., Diavatopoulos, D.A., van Crevel, R., et al. BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study. J. Infect. Dis. 212 (2015), 1930–1938.
35. [35] Bekkering, S., Joosten, L.A., van der Meer, J.W., Netea, M.G., Riksen, N.P., Trained innate immunity and atherosclerosis. Curr. Opin. Lipidol. 24 (2013), 487–492.
36. [36] Bekkering, S., Quintin, J., Joosten, L.A., van der Meer, J.W., Netea, M.G., Riksen, N.P., Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. Arterioscler. Thromb. Vasc. Biol. 34 (2014), 1731–1738.
37. [37] Lamb, D.J., Eales, L.J., Ferns, G.A., Immunization with bacillus Calmette-Guerin vaccine increases aortic atherosclerosis in the cholesterol-fed rabbit. Atherosclerosis 143 (1999), 105–113.
38. [38] Brasacchio, D., Okabe, J., Tikellis, C., Balcerczyk, A., George, P., Baker, E.K., et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 58 (2009), 1229–1236.
39. [39] Villeneuve, L.M., Reddy, M.A., Lanting, L.L., Wang, M., Meng, L., Natarajan, R., Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 9047–9052.
40. [40] El-Osta, A., Brasacchio, D., Yao, D., Pocai, A., Jones, P.L., Roeder, R.G., et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 205 (2008), 2409–2417.
41. [41] El-Osta, A., Glycemic memory. Curr. Opin. Lipidol. 23 (2012), 24–29.
42. [42] Miao, F., Chen, Z., Genuth, S., Paterson, A., Zhang, L., Wu, X., et al. Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes 63 (2014), 1748–1762.
43. [43] Bannon, P., Wood, S., Restivo, T., Campbell, L., Hardman, M.J., Mace, K.A., Diabetes induces stable intrinsic changes to myeloid cells that contribute to chronic inflammation during wound healing in mice. Dis. Model Mech. 6 (2013), 1434–1447.
44. [44] Rando, O.J., Simmons, R.A., I'm eating for two: parental dietary effects on offspring metabolism. Cell 161 (2015), 93–105.
45. [45] Alkemade, F.E., van Vliet, P., Henneman, P., van Dijk, K.W., Hierck, B.P., van Munsteren, J.C., et al. Prenatal exposure to apoE deficiency and postnatal hypercholesterolemia are associated with altered cell-specific lysine methyltransferase and histone methylation patterns in the vasculature. Am. J. Pathol. 176 (2010), 542–548.
46. [46] Lillycrop, K.A., Slater-Jefferies, J.L., Hanson, M.A., Godfrey, K.M., Jackson, A.A., Burdge, G.C., Induction of altered epigenetic regulation of the hepatic glucocorticoid receptor in the offspring of rats fed a protein-restricted diet during pregnancy suggests that reduced DNA methyltransferase-1 expression is involved in impaired DNA methylation and changes in histone modifications. Br. J. Nutr. 97 (2007), 1064–1073.
47. [47] Lumey, L.H., Stein, A.D., Kahn, H.S., van der Pal-de Bruin, K.M., Blauw, G.J., Zybert, P.A., et al. Cohort profile: the Dutch Hunger winter families study. Int. J. Epidemiol. 36 (2007), 1196–1204.
48. [48] Patti, M.E., Intergenerational programming of metabolic disease: evidence from human populations and experimental animal models. Cell. Mol. Life Sci. 70 (2013), 1597–1608.
49. [49] Carone, B.R., Fauquier, L., Habib, N., Shea, J.M., Hart, C.E., Li, R., et al. Paternally induced transgenerational environmental reprogramming of metabolic gene expression in mammals. Cell 143 (2010), 1084–1096.
50. [50] Ng, S.F., Lin, R.C., Laybutt, D.R., Barres, R., Owens, J.A., Morris, M.J., Chronic high-fat diet in fathers programs beta-cell dysfunction in female rat offspring. Nature 467 (2010), 963–966.
51. [51] Sanchez, I., Reynoso-Camacho, R., Salgado, L.M., The diet-induced metabolic syndrome is accompanied by whole-genome epigenetic changes. Genes Nutr., 10, 2015, 471.
52. [52] Chen, Q., Yan, M., Cao, Z., Li, X., Zhang, Y., Shi, J., et al. Sperm tsRNAs contribute to intergenerational inheritance of an acquired metabolic disorder. Science 351 (2016), 397–400.
53. [53] Donkin, I., Versteyhe, S., Ingerslev, L.R., Qian, K., Mechta, M., Nordkap, L., et al. Obesity and bariatric surgery drive epigenetic variation of spermatozoa in humans. Cell Metab. 25 (2016), 369–378.
54. [54] Sharma, U., Conine, C.C., Shea, J.M., Boskovic, A., Derr, A.G., Bing, X.Y., et al. Biogenesis and function of tRNA fragments during sperm maturation and fertilization in mammals. Science 351 (2016), 391–396.
55. [55] Gosselin, D., Glass, C.K., Epigenomics of macrophages. Immunol. Rev. 262 (2014), 96–112.
56. [56] Ivashkiv, L.B., Epigenetic regulation of macrophage polarization and function. Trends Immunol. 34 (2013), 216–223.
57. [57] Schmidt, S.V., Krebs, W., Ulas, T., Xue, J., Bassler, K., Gunther, P., et al. The transcriptional regulator network of human inflammatory macrophages is defined by open chromatin. Cell Res., 2016.
58. [58] Smale, S.T., Natoli, G., Transcriptional control of inflammatory responses. Cold Spring Harbor Perspect. Biol., 6, 2014, a016261.
59. [59] Smale, S.T., Tarakhovsky, A., Natoli, G., Chromatin contributions to the regulation of innate immunity. Annu. Rev. Immunol. 32 (2014), 489–511.
60. [60] Kaikkonen, M.U., Spann, N.J., Heinz, S., Romanoski, C.E., Allison, K.A., Stender, J.D., et al. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol. Cell 51 (2013), 310–325.
61. [61] Ostuni, R., Piccolo, V., Barozzi, I., Polletti, S., Termanini, A., Bonifacio, S., et al. Latent enhancers activated by stimulation in differentiated cells. Cell 152 (2013), 157–171.
62. [62] Saeed, S., Quintin, J., Kerstens, H.H., Rao, N.A., Aghajanirefah, A., Matarese, F., et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science, 345, 2014, 1251086.
63. [63] Donohoe, D.R., Bultman, S.J., Metaboloepigenetics interrelationships between energy metabolism and epigenetic control of gene expression. J. Cell. Physiol. 227 (2012), 3169–3177.
64. [64] Gut, P., Verdin, E., The nexus of chromatin regulation and intermediary metabolism. Nature 502 (2013), 489–498.
65. [65] Ganeshan, K., Chawla, A., Metabolic regulation of immune responses. Annu. Rev. Immunol. 32 (2014), 609–634.
66. [66] Pearce, E.L., Pearce, E.J., Metabolic pathways in immune cell activation and quiescence. Immunity 38 (2013), 633–643.
67. [67] Cheng, S.C., Quintin, J., Cramer, R.A., Shepardson, K.M., Saeed, S., Kumar, V., et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science, 345, 2014, 1250684.
68. [68] Tannahill, G.M., Curtis, A.M., Adamik, J., Palsson-McDermott, E.M., McGettrick, A.F., Goel, G., et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 496 (2013), 238–242.
69. [69] Bieghs, V., Walenbergh, S.M., Hendrikx, T., van Gorp, P.J., Verheyen, F., Olde Damink, S.W., et al. Trapping of oxidized LDL in lysosomes of Kupffer cells is a trigger for hepatic inflammation. Liver Int. 33 (2013), 1056–1061.
70. [70] Spann, N.J., Garmire, L.X., McDonald, J.G., Myers, D.S., Milne, S.B., Shibata, N., et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell 151 (2012), 138–152.
71. [71] Dorrestein, P.C., Mazmanian, S.K., Knight, R., Finding the missing links among metabolites, microbes, and the host. Immunity 40 (2014), 824–832.
72. [72] Sharon, G., Garg, N., Debelius, J., Knight, R., Dorrestein, P.C., Mazmanian, S.K., Specialized metabolites from the microbiome in health and disease. Cell Metab. 20 (2014), 719–730.
73. [73] Thorburn, A.N., Macia, L., Mackay, C.R., Diet, metabolites, and western-lifestyle inflammatory diseases. Immunity 40 (2014), 833–842.
74. [74] Palmer, A.C., Nutritionally mediated programming of the developing immune system. Adv. Nutr. 2 (2011), 377–395.
75. [75] Hildebrandt, M.A., Hoffmann, C., Sherrill-Mix, S.A., Keilbaugh, S.A., Hamady, M., Chen, Y.Y., et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 137 (2009), 1716–1724 (e1-2).
76. [76] Walker, A.W., Ince, J., Duncan, S.H., Webster, L.M., Holtrop, G., Ze, X., et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 5 (2011), 220–230.
77. [77] Chang, P.V., Hao, L., Offermanns, S., Medzhitov, R., The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 2247–2252.
78. [78] Pendyala, S., Walker, J.M., Holt, P.R., A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 142 (2012), 1100–1101 (e2).
79. [79] Chien, J.Y., Jerng, J.S., Yu, C.J., Yang, P.C., Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit. Care Med. 33 (2005), 1688–1693.
80. [80] Koeth, R.A., Wang, Z., Levison, B.S., Buffa, J.A., Org, E., Sheehy, B.T., et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19 (2013), 576–585.
81. [81] Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., Dugar, B., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472 (2011), 57–63.
82. [82] Cockerill, G.W., Rye, K.A., Gamble, J.R., Vadas, M.A., Barter, P.J., High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15 (1995), 1987–1994.
83. [83] De Nardo, D., Labzin, L.I., Kono, H., Seki, R., Schmidt, S.V., Beyer, M., et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat. Immunol. 15 (2014), 152–160.
84. [84] Vaisar, T., Pennathur, S., Green, P.S., Gharib, S.A., Hoofnagle, A.N., Cheung, M.C., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117 (2007), 746–756.
85. [85] Vickers, K.C., Palmisano, B.T., Shoucri, B.M., Shamburek, R.D., Remaley, A.T., MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13 (2011), 423–433.
86. [86] Badimon, J.J., Badimon, L., Fuster, V., Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85 (1990), 1234–1241.
87. [87] Plump, A.S., Scott, C.J., Breslow, J.L., Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 9607–9611.
88. [88] Rubin, E.M., Krauss, R.M., Spangler, E.A., Verstuyft, J.G., Clift, S.M., Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353 (1991), 265–267.
89. [89] Nissen, S.E., Tsunoda, T., Tuzcu, E.M., Schoenhagen, P., Cooper, C.J., Yasin, M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003), 2292–2300.
90. [90] Tardif, J.C., Gregoire, J., L'Allier, P.L., Ibrahim, R., Lesperance, J., Heinonen, T.M., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297 (2007), 1675–1682.
91. [91] Duivenvoorden, R., Tang, J., Cormode, D.P., Mieszawska, A.J., Izquierdo-Garcia, D., Ozcan, C., et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat. Commun., 5, 2014, 3065.
92. [92] Kamaly, N., Fredman, G., Subramanian, M., Gadde, S., Pesic, A., Cheung, L., et al. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 6506–6511.
93. [93] Bekkering, S., Joosten, L.A., van der Meer, J.W., Netea, M.G., Riksen, N.P., The epigenetic memory of monocytes and macrophages as a novel drug target in atherosclerosis. Clin. Ther. 37 (2015), 914–923.
94. [94] Loscalzo, J., Handy, D.E., Epigenetic modifications: basic mechanisms and role in cardiovascular disease (2013 Grover Conference series). Pulm. Circ. 4 (2014), 169–174.
95. [95] Seligson, D.B., Horvath, S., McBrian, M.A., Mah, V., Yu, H., Tze, S., et al. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 174 (2009), 1619–1628.
96. [96] Yamada, Y., Nishida, T., Horibe, H., Oguri, M., Kato, K., Sawabe, M., Identification of hypo- and hypermethylated genes related to atherosclerosis by a genome-wide analysis of DNA methylation. Int. J. Mol. Med. 33 (2014), 1355–1363.
97. [97] Nebbioso, A., Carafa, V., Benedetti, R., Altucci, L., Trials with ‘epigenetic’ drugs: an update. Mol. Oncol. 6 (2012), 657–682.
98. [98] Shakespear, M.R., Halili, M.A., Irvine, K.M., Fairlie, D.P., Sweet, M.J., Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 32 (2011), 335–343.
99. [99] Choi, J.H., Nam, K.H., Kim, J., Baek, M.W., Park, J.E., Park, H.Y., et al. Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25 (2005), 2404–2409.
100. [100] De Santa, F., Narang, V., Yap, Z.H., Tusi, B.K., Burgold, T., Austenaa, L., et al. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J. 28 (2009), 3341–3352.
101. [101] Kruidenier, L., Chung, C.W., Cheng, Z., Liddle, J., Che, K., Joberty, G., et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488 (2012), 404–408.
102. [102] Satoh, T., Takeuchi, O., Vandenbon, A., Yasuda, K., Tanaka, Y., Kumagai, Y., et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat. Immunol. 11 (2010), 936–944.
103. [103] Mullican, S.E., Gaddis, C.A., Alenghat, T., Nair, M.G., Giacomin, P.R., Everett, L.J., et al. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev. 25 (2011), 2480–2488.
104. [104] Hoeksema, M.A., Gijbels, M.J., Van den Bossche, J., van der Velden, S., Sijm, A., Neele, A.E., et al. Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions. EMBO Mol. Med. 6 (2014), 1124–1132.
105. [105] Consortium, U.I.G., Barrett, J.C., Lee, J.C., Lees, C.W., Prescott, N.J., Anderson, C.A., et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat. Genet. 41 (2009), 1330–1334.
106. [106] Cao, Q., Rong, S., Repa, J.J., Clair, R. St., Parks, J.S., Mishra, N., Histone deacetylase 9 represses cholesterol efflux and alternatively activated macrophages in atherosclerosis development. Arterioscler. Thromb. Vasc. Biol. 34 (2014), 1871–1879.
107. [107] Schoors, S., De Bock, K., Cantelmo, A.R., Georgiadou, M., Ghesquiere, B., Cauwenberghs, S., et al. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 19 (2014), 37–48.
108. [108] Xu, W., Deng, Y.Y., Yang, L., Zhao, S., Liu, J., Zhao, Z., et al. Metformin ameliorates the proinflammatory state in patients with carotid artery atherosclerosis through sirtuin 1 induction. Transl. Res. 166 (2015), 451–458.
109. [109] Vasamsetti, S.B., Karnewar, S., Kanugula, A.K., Thatipalli, A.R., Kumar, J.M., Kotamraju, S., Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes 64 (2015), 2028–2041.
110. [110] Riksen, N.P., Tack, C.J., The cardiovascular effects of metformin: lost in translation. Curr. Opin. Lipidol. 25 (2014), 446–451.
111. [111] Preiss, D., Lloyd, S.M., Ford, I., McMurray, J.J., Holman, R.R., Welsh, P., et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol. 2 (2014), 116–124.